FDA Brief

Warning letters Drugs

FDA warning letter to

Indiangoods.shop

MediumIssued Jun 17Posted Jun 23Center for Drug Evaluation and Research (CDER)

FDA warned website Indiangoods.shop that three herbal sexual-performance capsules it sells are unapproved new drugs.

What happened

FDA reviewed the website https://www.indiangoods.shop in May 2026 and found three products promoted with claims to improve stamina, raise testosterone, or treat sexual weakness. FDA said these claims make the products drugs, that they are not generally recognized as safe and effective, and that no FDA-approved application exists for any of them. Selling them across state lines is therefore illegal under the Federal Food, Drug, and Cosmetic Act.

What FDA found

  1. The website text claims the products treat or affect body functions, so FDA treats them as drugs.

    FD&C Act section 201(g)(1), 21 U.S.C. 321(g)(1)
  2. Website wording such as "helps increase testosterone levels" and "Make Love Longer than ever" shows the products are intended for drug use.

    21 CFR 201.128
  3. The products are "new drugs" because they are not generally recognized as safe and effective for their labeled uses.

    FD&C Act section 201(p), 21 U.S.C. 321(p)
  4. No FDA-approved application is in effect for any of the three products.

    FD&C Act section 505(a), 21 U.S.C. 355(a)
  5. Offering these unapproved drugs for sale and shipment violates the law.

    FD&C Act sections 301(d) and 505(a), 21 U.S.C. 331(d) and 355(a)

What FDA wants

FDA tells the company to find the root causes, correct and prevent the violations, and send a written response with supporting documents to FDAAdvisory@fda.hhs.gov within 15 business days, with reference number 729068 in the subject line.

Who should pay attention

  • online sellers and website operators listing Ayurvedic or herbal supplements
  • brands whose products are resold by third-party websites
  • US importers and distributors of Indian herbal products

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk